Transparency Market Research in its new report titled, “Batten Disease Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the batten disease market. The TMR report anticipates that the increase in research and development, introduction of novel disease therapies, rise in demand for effective therapies among patients, and upsurge in prevalence of the disease will drive the batten disease market during the forecast period i.e, 2018-2026.
The TMR report has segmented the global batten disease market based on disease type, treatment and region. Based on disease type, the batten disease market is categorized into juvenile NCL, infantile NCL (INCL), late infantile NCL and adult NCL. In terms of treatment, the batten disease market is classified into occupational therapies, and physical therapies. As yet, no specific treatment is known that can reverse the symptoms of batten disease but seizures can be used reduced with anticonvulsant drugs, and other medical problems can be reduced and controlled by certain therapies. The batten therapeutics pipeline comprises of more number of gene therapy, small molecules, enzyme therapies, and others drug candidates that are developed as recombinant peptides and protein. In batten disease, t most of the drug candidates for treatment of the disease are in the clinical stage of development. This is expected to lead to more certainty of drug approvals for the treatment of batten disease, with positive clinical results, in coming years.
On a geographical perspective, the batten disease market is segmented in five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe accounted for major share of the Whipple’s disease market. According to Research Office Legislative Council Secretariat report there are over 30 million people suffering from rare diseases in the U.S. The strong focus on research and development, the government aids to promote R&D, such as research grants, tax credits and fee waivers contribute to the growth of the market. Europe was the trailing second region in terms of revenues in orphan drugs market. According to Research Office Legislative Council Secretariat report 2015, over 30 million peoples were suffering from rare diseases in the European Union. The incentives offered to promote the manufacturing of orphan drugs in the region, such as 10-year period of marketing exclusivity, research grants and reduced fees for marketing authorization applications aid in the growth of the market. Over 1,805 drugs have been granted orphan drug status in the European Union and over 128 drugs were granted marketing authority during 2000 to 2016. For instance, on December 2017, PLX-100 a Polaryx Therapeutics drug, received Orphan Drug Designation from the US FDA for the treatment of NCLs.
Some of the major companies operating in the global batten disease market are profiled in this report to give a better competitive analysis and these include Abeo Therapeutics Inc, Evotec AG, RegenxBio Inc, Spark Therapeutics Inc, BioMarin Pharmaceuticals, Seneb BioSciences, Inc., and Polaryx Therapeutics.
About Us
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: [email protected]